US Patent 8,204,763: Scope, Claims, Expiration, and Thalidomide Patent Landscape

US Patent 8,204,763 is a Celgene patent directed to a controlled-distribution process for thalidomide and other teratogenic drugs. Its independent claim does not protect thalidomide as a chemical compound, a tablet formulation, or a manufacturing process. It targets the coordinated use of prescriber, patient, pharmacy, distributor, registration, counseling, informed-consent, and prescription-generation controls.

The principal commercial relevance was Celgene's Thalomid distribution system and its associated pregnancy-prevention controls. Because the patent's term has expired, it does not presently create a blocking patent right against generic thalidomide distribution. Its claim structure remains relevant to historical litigation, freedom-to-operate analysis, and the design of modern drug-distribution programs.

What does US Patent 8,204,763 cover?

US Patent 8,204,763 covers a method of treating a male patient with a disease or condition responsive to a teratogenic drug when the drug is distributed through a controlled prescription process.

The independent claim requires all of the following:

Claim element	Scope
Patient	Male patient
Drug	Teratogenic drug responsive to the patient's disease or condition
Distribution	Pharmacy distributes the drug only after receiving a prescription
Prescriber and pharmacy	Both are registered with the distributor
Patient assessment	Patient's ability to understand and carry out instructions is determined
Counseling	Verbal and written warnings address fetal exposure, birth defects, contraception failure, and barrier contraception
Patient acknowledgment	Patient acknowledges the warnings
Patient registration	Patient is registered with the distributor
Prescription generation	A computer-readable medium generates the prescription after the required acknowledgments and registrations
Treatment	The drug is administered to the patient

The claim is therefore a regulated-distribution method claim, not a conventional pharmaceutical composition claim.

How should claim 1 be construed?

Claim 1 is narrow in several important respects.

Male-patient limitation

The claim expressly requires treatment of a male patient. A distribution program limited to female patients would not literally satisfy this limitation. A program covering both sexes could fall within the claim when used for male patients, assuming the remaining elements are present.

The male-patient limitation reflects the risk that thalidomide may expose a fetus through semen. The claim therefore extends beyond preventing a treated woman from becoming pregnant. It covers counseling and controls directed to a treated man's sexual partner and the risk of contraception failure.

Teratogenic-drug limitation

The claim is not limited by chemical name. It applies to a "teratogenic drug" responsive to the relevant disease or condition. Thalidomide is the commercial and technical focus, but the claim language is potentially broader than thalidomide.

The drug must satisfy both parts of the limitation:

It must be teratogenic.
It must be used to treat a disease or condition for which the patient responds to the drug.

A non-teratogenic drug, or a teratogenic drug used outside a responsive treatment context, would not meet the express claim language.

Computer-readable storage medium

Claim 1 requires registration and prescription-generation steps performed "via a computer readable storage medium." This limitation ties the claimed method to an electronic or computer-supported distribution infrastructure.

A purely paper-based process could present a noninfringement argument if it does not use the claimed computer-readable medium. That argument would depend on the actual operation of the program, including whether paper forms merely document a process implemented by a computer system elsewhere.

Pharmacy distribution restriction

The pharmacy must distribute the drug only after receiving a prescription. This is a separate limitation from the electronic prescription-generation requirement. A system could use electronic registration but still fail the claim if the pharmacy distributes the drug without receiving the required prescription.

Patient acknowledgment and registration

The claim requires both:

Acknowledgment of the warnings; and
Registration of the patient with the distributor.

A program that provides counseling but does not obtain a formal acknowledgment may not satisfy the claim. Conversely, patient registration alone is insufficient without the required warnings and acknowledgment.

What additional obligations are protected by claim 2?

Claim 2 narrows claim 1 by requiring acknowledgment of one or more specific items. The items include:

The patient must not take the drug if unprotected sex cannot be avoided.
The patient understands the potential for birth defects.
The prescriber advised the patient about barrier contraception.
The patient must notify the prescriber if a sexual partner is pregnant or may be pregnant.
The drug is for the patient's use only and must not be shared.
The patient read the information brochure or viewed the information film.
The patient must not donate semen or blood during treatment.
The prescriber answered the patient's treatment questions.
Participation in a survey and patient registry is required.

The use of "one or more" makes claim 2 less demanding than a requirement that every listed acknowledgment be obtained. The accused program must still fall within claim 1 before claim 2 can apply.

What does claim 3 add?

Claim 3 requires a written authorization by the prescriber.

This limitation is significant because it separates the physician's authorization from the broader prescription-generation process. A controlled-distribution program using an electronic prescription but no written prescriber authorization may avoid literal infringement of claim 3, while potentially remaining within claim 1.

What does claim 4 protect?

Claim 4 requires:

A written informed consent; and
Pharmacy dispensing only when the patient presents that written consent.

This is the most document-intensive limitation in the asserted claim set. A system using electronic consent, electronic certification, or distributor-side confirmation may not literally satisfy the written-consent and patient-presentation requirements, depending on the record and applicable claim construction.

What patents protect Thalomid and its distribution system?

The relevant patent estate has historically included several categories:

Patent category	Subject matter	Relevance to US 8,204,763
Compound patents	Thalidomide or related chemical entities	Separate from the claimed distribution method
Use patents	Treatment of cancer, inflammatory disease, or other conditions	May restrict particular therapeutic uses
Distribution patents	Registration, counseling, prescription control, and pharmacy authorization	Directly related to US 8,204,763
Formulation patents	Tablet composition, excipients, dosage form, or release profile	Not covered by the claims provided
Manufacturing patents	Synthesis, purification, or tablet production	Not covered by the claims provided
REMS-related controls	FDA-required risk-management procedures	Regulatory obligations, not automatically patent rights

US 8,204,763 is best classified as a risk-management and controlled-distribution patent. It does not claim a thalidomide molecule, a specific salt, a tablet coating, or a manufacturing step.

When did US Patent 8,204,763 lose exclusivity?

The patent has expired. Its term was governed by the 20-year patent-term framework applicable to the underlying application family, subject to any patent-term adjustment or terminal disclaimer reflected in the USPTO record.[1]

The patent is therefore not a current exclusionary right against generic thalidomide manufacturers or pharmacies. Expiration does not eliminate the historical importance of the patent, but it removes ordinary patent-infringement exposure for post-expiration conduct.

Patent expiration also does not eliminate FDA-imposed safety controls. A manufacturer may still have to comply with the applicable FDA risk-management requirements even though the distribution method is no longer patent-protected.[2]

What is the Orange Book status of US 8,204,763?

US 8,204,763 should be distinguished from product patents listed for an approved thalidomide product.

Orange Book listing generally concerns patents submitted by an NDA holder that claim the approved drug, an approved method of using the drug, or the drug's approved formulation. A controlled-distribution process patent is not automatically eligible for listing merely because it relates commercially to the product.

The patent is not a current commercial barrier to an abbreviated new drug application for thalidomide. Generic applicants must address any unexpired Orange Book-listed patents and applicable exclusivity periods, but an expired distribution-system patent does not support a current Paragraph IV exclusion period.

What Paragraph IV challenges affected thalidomide?

A Paragraph IV certification concerns an ANDA applicant's assertion that a listed patent is invalid, unenforceable, or will not be infringed. For thalidomide, Paragraph IV risk historically centered on:

Compound and composition patents;
Approved-use patents;
Formulation or dosage patents;
Any listed distribution or method-of-use patent still in force.

US 8,204,763 could have been relevant to a Paragraph IV analysis if it had been listed and unexpired at the time of an ANDA filing. Its method claim would have raised infringement questions concerning the generic manufacturer's pharmacy controls, patient registration process, electronic authorization system, and required counseling.

The practical impact would have depended on whether the ANDA applicant certified that it would use the patented distribution method. A generic manufacturer could seek a noninfringing design by:

Separating its electronic enrollment system from the pharmacy;
Avoiding the claimed written-consent presentation requirement;
Using a different patient-authorization architecture;
Omitting claim-specific acknowledgment items where legally permissible;
Using FDA-required controls without reproducing every patent limitation.

Does US 8,204,763 create biosimilar risk?

No. Thalidomide is a small-molecule drug, not a biologic. The relevant competitive pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k) of the Public Health Service Act.[3]

The patent is therefore relevant to generic-drug strategy, not biosimilar interchangeability or biologic reference-product exclusivity.

What formulations are protected by US 8,204,763?

None are claimed expressly.

The claims do not recite:

A tablet;
A capsule;
A particular dosage strength;
A specific excipient;
A release profile;
A coating;
A particle-size distribution;
A polymorph;
A salt or solvate;
A formulation manufacturing step.

The patent could apply to a drug supplied in different dosage forms if the distribution and patient-management limitations are met. That does not mean the patent protects those dosage forms as products.

Does the patent protect thalidomide manufacturing?

No. There is no claim limitation directed to synthesis, reaction conditions, purification, crystallization, blending, compression, encapsulation, packaging, or quality-control testing.

A manufacturer could therefore avoid the patent's claimed subject matter by producing thalidomide through any lawful manufacturing process, provided its downstream distribution activities do not satisfy all limitations of an enforceable claim. Because the patent has expired, this distinction is now primarily relevant to historical freedom-to-operate analysis.

How strong was the patent estate?

The patent was commercially important while unexpired because it targeted operational infrastructure rather than the drug molecule alone.

Strength factor	Assessment
Commercial relevance	High during operation of a mandatory controlled-distribution program
Chemical coverage	None
Formulation coverage	None
Manufacturing coverage	None
Regulatory overlap	High
Design-around potential	Moderate to high
Claim breadth	Moderate; broad drug category but numerous process limitations
Current enforceability	None after expiration
Generic launch barrier today	None from this patent

Its principal weakness was claim density. An accused party could attack individual elements, including the male-patient requirement, computer-readable-medium language, written acknowledgment, prescriber authorization, or pharmacy receipt and verification steps.

The risk was also affected by divided-performance issues. A distributor, prescriber, pharmacy, and patient may perform different claim steps. A patent owner would need to establish direct infringement under the applicable single-entity or direction-and-control doctrine, or pursue induced infringement based on knowledge and encouragement.[4]

What litigation and settlement issues were relevant?

The main litigation issues for a patent of this type would include:

Whether the accused distribution program used the claimed registration architecture;
Whether the pharmacy received the required prescription before dispensing;
Whether patient consent was written or electronic;
Whether a distributor generated the prescription;
Whether all claim steps were performed by, or attributable to, one entity;
Whether FDA-required conduct was being asserted as patent infringement;
Whether the claims were anticipated or obvious in view of earlier thalidomide risk-management programs;
Whether the patent's claims were directed to patent-eligible subject matter after Bilski, Mayo, and Alice.

The record provided does not establish a current, enforceable litigation threat arising from US 8,204,763. Any historical settlement involving thalidomide distribution, generic entry, or other Celgene patents should not be treated as a continuing restriction after expiration unless the settlement included independent contractual terms.

How does US 8,204,763 compare with competing drug patent estates?

Drug or product	Competitive relationship	Patent-landscape distinction
Thalomid, thalidomide	Reference product and direct subject	Distribution controls and historical thalidomide patents
Generic thalidomide	Direct generic competition	ANDA and product-patent analysis; no current barrier from US 8,204,763
Revlimid, lenalidomide	Related immunomodulatory drug	Separate compound, formulation, use, and distribution estate
Pomalyst, pomalidomide	Related immunomodulatory drug	Separate composition, use, and commercial exclusivity analysis
Other teratogenic drugs	Potentially within claim language	Must satisfy every method limitation; no automatic coverage

The claim's use of a generic "teratogenic drug" concept creates theoretical reach beyond thalidomide. Commercially, however, the patent's prosecution history, written description, enablement, and obviousness record would be central to assessing whether that reach could be enforced against unrelated drug programs.

What generic launch risks remain?

US 8,204,763 presents no current generic-launch block because it has expired. Remaining launch risks would come from other sources:

Unexpired compound or formulation patents.
Unexpired method-of-use patents.
Orange Book-listed patents associated with the reference product.
FDA safety-program requirements.
Labeling restrictions and restricted-distribution controls.
Manufacturing and supply-chain qualification.
State pharmacy and controlled-substance requirements.
Commercial access to pharmacies and wholesalers.

A generic manufacturer should not assume that patent expiration eliminates the need for a controlled-distribution program. The FDA's safety controls and the patent estate are separate legal systems.

What is the commercial exposure?

The patent's historical value was tied to the sales of products distributed through Celgene's controlled program, principally Thalomid. Its expiration does not by itself determine thalidomide revenue, because revenue depends on indication, pricing, generic competition, prescribing volume, and FDA controls.

For Celgene and later Bristol Myers Squibb, the larger commercial exposure arose from the broader immunomodulatory portfolio, particularly Revlimid and Pomalyst. US 8,204,763 should not be used as a proxy for the value or remaining exclusivity of those products. Their compound, formulation, method-of-use, and distribution patents require separate analysis.

Key Takeaways

US 8,204,763 is a controlled-distribution method patent focused on male patients receiving a teratogenic drug.
Its core requirements are patient assessment, counseling, acknowledgment, registration, prescription generation, and pharmacy-controlled distribution.
It does not claim thalidomide as a compound, formulation, or manufacturing process.
Claims 2 through 4 add specific acknowledgment, written-authorization, and written-consent requirements.
The patent has expired and does not create a current generic-launch barrier.
Thalidomide is a small molecule, so biosimilar rules do not apply.
FDA risk-management requirements remain separate from patent rights.
The principal historical infringement issues involved divided performance, electronic registration systems, written consent, and pharmacy authorization.
Any current thalidomide freedom-to-operate review must focus on other patents, regulatory controls, and commercial supply requirements.

FAQs

Can a generic manufacturer use a different thalidomide REMS system?

Yes, after expiration of US 8,204,763, a generic manufacturer is not blocked by this patent from using a different distribution architecture. It must still satisfy FDA requirements and any other enforceable patents.

Does the patent cover male contraception for all teratogenic drugs?

The claim is not limited by chemical name, but it requires every listed method step. The theoretical drug scope is broad, while the operational limitations materially narrow enforceability.

Can electronic informed consent infringe claim 4?

Claim 4 expressly requires written informed consent and presentation of that written consent to the pharmacy. An electronic process would require fact-specific analysis and would not automatically satisfy those limitations.

Does patient registration alone infringe US 8,204,763?

No. Patient registration is only one limitation. The claim also requires counseling, acknowledgment, prescriber and pharmacy registration, prescription generation, pharmacy receipt of the prescription, and administration of the drug.

Is US 8,204,763 relevant to lenalidomide or pomalidomide?

It may be relevant historically to similar controlled-distribution concepts, but it does not determine the patent position for Revlimid or Pomalyst. Those products require separate analysis of their own compound, formulation, method-of-use, and distribution patents.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation under 35 U.S.C. § 154. https://www.uspto.gov
U.S. Food and Drug Administration. (n.d.). Risk evaluation and mitigation strategies. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application ANDA process and biosimilar product regulation. https://www.fda.gov/drugs
United States Patent and Trademark Office. (n.d.). Manual of Patent Examining Procedure, infringement and related patent doctrines. https://www.uspto.gov/web/offices/pac/mpep/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
United States Patent and Trademark Office. (2012). U.S. Patent No. 8,204,763: Methods and systems for managing a drug distribution program. https://patents.google.com/patent/US8204763B2/en

Details for Patent: 8,204,763

Summary for Patent: 8,204,763